Literature DB >> 2126347

Behavioural, biochemical and electrophysiological studies on the motor depressant and stimulant effects of bromocriptine.

D M Jackson1, L P Martin, L G Larsson, R F Cox, B L Waszczak, S B Ross.   

Abstract

Bromocriptine (BRC) produced a biphasic behavioural effect in mice; an early depressant phase which lasted for about 1 h and a later stimulant phase which lasted from about 1 to 5 h. The stimulation was blocked with SCH23390. Both phases of activity were accompanied by marked striatal DA autoreceptor effects as indicated by reductions in dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) levels and by a reduction in the accumulation of DOPA (after inhibition of nigrostriatal DA nerve firing and DOPA decarboxylase). However, while the autoreceptor effects were still evident during the behavioural stimulant phase, there was a gradual rise in DOPAC and HVA from 1 to 4 h after injection, indicating a gradually increasing DA turnover. We were unable, using a variety of behavioural and biochemical paradigms, to demonstrate any change in DA autoreceptor sensitivity after one dose of BRC. In electrophysiological studies, however, it was found that prior exposure of rats to one dose of BRC rendered them subsensitive to the rate-inhibiting effects of a second dose of BRC, as measured in anaesthetized animals using extracellular single cell recordings of identified DA neurons in the substantia nigra pars compacta. It is concluded firstly, that the stimulant phase of BRC in mice occurs despite continued occupation of the DA autoreceptors by BRC because adequate endogenous DA is available to provide the required D1 receptor stimulation and secondly, that the terminal autoreceptors in the striatum (as assessed in mice using biochemical techniques) may be regulated differently to the somatodendritic autoreceptors (as assessed electrophysiologically in rats).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2126347     DOI: 10.1007/bf00169440

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  36 in total

1.  Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.

Authors:  A M Johnson; D M Loew; J M Vigouret
Journal:  Br J Pharmacol       Date:  1976-01       Impact factor: 8.739

2.  Dopamine D-2 receptor agonist-induced behavioural depression: critical dependence upon postsynaptic dopamine D-1 function. A behavioural and biochemical study.

Authors:  D M Jackson; S B Ross; L G Larsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

3.  Stereotyped behaviour in response to the selective D-2 dopamine receptor agonist RU 24213 is enhanced by pretreatment with the selective D-1 agonist SK&F 38393.

Authors:  M Mashurano; J L Waddington
Journal:  Neuropharmacology       Date:  1986-08       Impact factor: 5.250

4.  Interaction of ergot drugs with central monoamine systems. Evidence for a high potential in the treatment of mental and neurological disorders.

Authors:  K Fuxe; B B Fredholm; L F Agnati; S O Ogren; B J Everitt; G Jonsson; J A Gustafsson
Journal:  Pharmacology       Date:  1978       Impact factor: 2.547

5.  Dopamine"autoreceptors": pharmacological characterization by microiontophoretic single cell recording studies.

Authors:  G K Aghajanian; B S Bunney
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-03       Impact factor: 3.000

6.  Rapid desensitization of presynaptic dopamine autoreceptors during exposure to exogenous dopamine.

Authors:  S Arbilla; J Z Nowak; S Z Langer
Journal:  Brain Res       Date:  1985-06-24       Impact factor: 3.252

7.  Evidence for selective and long-lasting stimulation of "regulatory" dopamine-receptors by bromocriptine (CB 154).

Authors:  G di Chiara; M L Porceddu; L Vargiu; E Stefanini; G L Gessa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

8.  Dopamine-mediated behaviours produced in naive mice by bromocriptine plus SKF 38393.

Authors:  D M Jackson; S B Ross; M Hashizume
Journal:  J Pharm Pharmacol       Date:  1988-03       Impact factor: 3.765

9.  Evidence for an irreversible interaction of bromocryptine with central dopamine receptors.

Authors:  M J Bannon; A A Grace; B S Bunney; R H Roth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-05       Impact factor: 3.000

10.  The involvement of dopamine D1 and D2 receptors in the locomotor stimulation produced by (+)-amphetamine in naive and dopamine-depleted mice.

Authors:  S B Ross; D M Jackson; S R Edwards
Journal:  Pharmacol Toxicol       Date:  1989-01
View more
  4 in total

1.  Differential regional and kinetics effects of piribedil and bromocriptine on dopamine metabolites: a brain microdialysis study in freely moving rats.

Authors:  R Pagliari; L Peyrin; O Crambes
Journal:  J Neural Transm Gen Sect       Date:  1995

2.  Bromocriptine and quinpirole, but not 7-OH-DPAT or SKF 38393, potentiate the inhibitory effect of L-NAME on ethanol-induced locomotor activity in mice.

Authors:  I Tayfun Uzbay; Hakan Kayir
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-21       Impact factor: 3.000

Review 3.  Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis.

Authors:  James W Bales; Amy K Wagner; Anthony E Kline; C Edward Dixon
Journal:  Neurosci Biobehav Rev       Date:  2009-04-01       Impact factor: 8.989

4.  Time course of bromocriptine induced excitation in the rat: behavioural and biochemical studies.

Authors:  D M Jackson; N Mohell; J Georgiev; A Bengtsson; L G Larsson; O Magnusson; S B Ross
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-02       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.